Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Imaxitinib Plus Chemo-immunotherapy for Locally Advanced HNSCC
NCT07457346Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Pathological Complete Response Rate and Objective Response Rate at 6 weeks. Started Jan 2026; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07457346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457346.